8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

_____________________________________________________________________

Date of Report (Date of earliest event reported): June 24, 2021 (June 23, 2021)

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

300 Boston Scientific Way, Marlborough, Massachusetts                 01752-1234

(Address of principal executive offices)                           (Zip Code)

(508) 683-4000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

(d) Election of Directors

On June 23, 2021 the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”), upon the recommendation of the Nominating and Governance Committee, increased the number of directors comprising the Board from nine to ten and appointed David S. Wichmann to be a director of the Company, filling the vacancy created by such an increase, to hold office until the next annual meeting of stockholders, in each case, effective June 23, 2021. The Board expects to appoint Mr. Wichmann to one or more committees of the Board at a later date. As of the filing of this Current Report on Form 8-K, the Board has not determined the committee assignments for Mr. Wichmann. The Company will provide the foregoing information by filing an amendment to this Current Report on Form 8-K after the information is determined or becomes available.

Under the Company’s non-employee director compensation program (the “Program”), Mr. Wichmann will receive standard non-employee director compensation, prorated for the time period from the effective date of his appointment to the date of the Company’s 2022 annual meeting of stockholders (the “2022 Annual Meeting”), which includes (i) a cash retainer of approximately $99,500 (representing the prorated amount of the Program’s annual cash retainer of $115,000, which can be received in cash or an equity alternative) and (ii) an equity award valued at approximately $177,400 (representing the prorated amount of the Program’s annual grant of equity having a value of $205,000) vesting at the end of his term. The actual number of shares to be granted to Mr. Wichmann will be determined on the date of grant, July 1, 2021, which is the first business day of the month following the month in which he will be appointed.

In connection with his appointment to the Board, the Company intends to enter into an indemnification agreement with Mr. Wichmann in substantially the same form as the Company has entered into with each of the Company’s existing directors and as previously filed with the Securities and Exchange Commission.

Mr. Wichmann does not have any arrangement or understanding with any other person pursuant to which he was appointed as a director. Mr. Wichmann does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

ITEM 7.01.    REGULATION FD DISCLOSURE.

On June 24, 2021, the Company issued a press release (the “Press Release”) announcing Mr. Wichmann’s appointment to the Board. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01.    FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Document

FOR IMMEDIATE RELEASE

BOSTON SCIENTIFIC ELECTS DAVID S. WICHMANN TO BOARD OF DIRECTORS

Marlborough, Mass. (June 24, 2021) -- Boston Scientific Corporation (NYSE: BSX) announced today the election of David S. Wichmann to its board of directors, effective immediately.

Wichmann recently served as chief executive officer of UnitedHealth Group from 2017 to 2021. His career at UnitedHealth Group spans 23 years in roles of increasing responsibility leading the growth, diversification and performance of the company’s domestic and international businesses, including president, chief financial officer, and head of operations and commercial markets. Prior to joining UnitedHealth Group, Wichmann was a partner at the global accounting firm Arthur Andersen & Co. He has served on the boards of UnitedHealth Group Incorporated and Tennant Company and holds a B.S. in accounting from Illinois State University.

“From his experience leading one of the largest health care organizations in the world, Dave has unique insights about opportunities to improve patient outcomes while also taking costs out of the health care system,” said Mike Mahoney, chief executive officer and chairman of the board, Boston Scientific. “We welcome him to our board and look forward to working together to continue to deliver meaningful innovation to patients and health care providers.”

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.